Collegium Pharmaceutical Inc. Insider Trading

COLL

Last 12 months

Insiders sold $7.24M and bought nothing on the open market.

66% of the selling was scheduled in advance under 10b5-1 plans. Director John A. Fallon sold $1.65M on Nov 12, 2025, 35% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2017.

Net open-market

−$7.24M

0 buys · 11 sales

Under a 10b5-1 plan

66%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

May 2017

May 12, 2017

Get an email when COLL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 18	John Gordon Freund Director	SoldNo plan	20	$34.05	$681	<0.1%	Form 4
May 15	John Gordon Freund Director	SoldNo plan	4,127	$34.54	143K	3.4%	Form 4
May 13	Nancy Lurker Director	SoldNo plan	4,500	$35.97	162K	20%	Form 4
May 11	Garen G Bohlin Director	SoldNo plan	8,700	$37.18	323K	12%	Form 4
Mar 18	David Dieter EVP & General Counsel	Sold10b5-1 plan	13,976	$34.92	488K	15%	Form 4
Mar 9	David Dieter EVP & General Counsel	Sold10b5-1 plan	6,224	$36.65	228K	6.4%	Form 4
Mar 3	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan 2 parts	49,976	$40.40 average	$2.02M	41%	Form 4
Dec 8, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan 2 parts	17,600	$48.17 average	848K	15%	Form 4
Dec 5, 2025	Rita J. Balice-Gordon Director	SoldNo plan	3,650	$47.03	172K	6.5%	Form 4
Nov 12, 2025	John A. Fallon Director	SoldNo plan	34,853	$47.21	$1.65M	35%	Form 4
Nov 6, 2025	Colleen Tupper EVP & Chief Financial Officer	Sold10b5-1 plan 2 parts	30,000	$40.53 average	$1.22M	19%	Form 4
Aug 29, 2025	Thomas B Smith EVP and Chief Medical Officer	SoldNo plan	17,478	$38.42	672K	20%	Form 4
Aug 18, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan	16,389	$38.21	626K	14%	Form 4
Aug 15, 2025	Gino Santini Director	SoldNo plan	5,405	$37.19	201K	5.4%	Form 4
Aug 13, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan	4,861	$38.03	185K	4.5%	Form 4
Aug 13, 2025	Rubric Capital Management LP Large holder	SoldNo plan	25,000	$37.85	946K	0.8%	Form 4
Aug 8, 2025	John Gordon Freund Director	SoldNo plan	11,659	$34.36	401K	10%	Form 4
Jun 9, 2025	John Gordon Freund Director	SoldNo plan	6,601	$30.62	202K	5.5%	Form 4
Mar 20, 2025 – Mar 21, 2025	Colleen Tupper EVP & Chief Financial Officer	Sold10b5-1 plan 2 parts	7,602	$30.03 average	228K	4.6%	Form 4
Mar 20, 2025 – Mar 21, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan 2 parts	20,808	$30.03 average	625K	17%	Form 4
Mar 14, 2025	Colleen Tupper EVP & Chief Financial Officer	Sold10b5-1 plan	977	$30.00	29K	0.6%	Form 4
Mar 14, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan	2,255	$30.00	68K	1.8%	Form 4
Mar 11, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan	15,387	$30.00	462K	11%	Form 4
Mar 11, 2025	Colleen Tupper EVP & Chief Financial Officer	Sold10b5-1 plan	10,445	$30.01	313K	5.9%	Form 4
Mar 6, 2025 – Mar 7, 2025	Colleen Tupper EVP & Chief Financial Officer	Sold10b5-1 plan 2 parts	3,453	$30.00 average	104K	1.9%	Form 4
Mar 6, 2025 – Mar 7, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan 2 parts	5,643	$30.00 average	169K	3.8%	Form 4
Mar 6, 2025	Scott Dreyer EVP & Chief Commercial Officer	Sold10b5-1 plan	15,387	$30.00	462K	11%	Form 4
Mar 4, 2025 – Mar 6, 2025	Shirley R. Kuhlmann EVP and General Counsel	SoldNo plan 3 parts	86,067	$28.20 average	$2.43M	44%	Form 4
Jan 10, 2025	Shirley R. Kuhlmann EVP and General Counsel	Sold10b5-1 plan 2 parts	27,500	$33.04 average	909K	19%	Form 4

May 18No plan
John Gordon Freund
Director · sold 20 at $34.05
$681
<0.1% of stake
May 15No plan
John Gordon Freund
Director · sold 4,127 at $34.54
143K
3.4% of stake
May 13No plan
Nancy Lurker
Director · sold 4,500 at $35.97
162K
20% of stake
May 11No plan
Garen G Bohlin
Director · sold 8,700 at $37.18
323K
12% of stake
Mar 1810b5-1 plan
David Dieter
EVP & General Counsel · sold 13,976 at $34.92
488K
15% of stake
Mar 910b5-1 plan
David Dieter
EVP & General Counsel · sold 6,224 at $36.65
228K
6.4% of stake
Mar 310b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 49,976 at avg $40.40
$2.02M
41% of stake
Dec 8, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 17,600 at avg $48.17
848K
15% of stake
Dec 5, 2025No plan
Rita J. Balice-Gordon
Director · sold 3,650 at $47.03
172K
6.5% of stake
Nov 12, 2025No plan
John A. Fallon
Director · sold 34,853 at $47.21
$1.65M
35% of stake
Nov 6, 202510b5-1 plan
Colleen Tupper
EVP & Chief Financial Officer · sold 30,000 at avg $40.53
$1.22M
19% of stake
Aug 29, 2025No plan
Thomas B Smith
EVP and Chief Medical Officer · sold 17,478 at $38.42
672K
20% of stake
Aug 18, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 16,389 at $38.21
626K
14% of stake
Aug 15, 2025No plan
Gino Santini
Director · sold 5,405 at $37.19
201K
5.4% of stake
Aug 13, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 4,861 at $38.03
185K
4.5% of stake
Aug 13, 2025No plan
Rubric Capital Management LP
Large holder · sold 25,000 at $37.85
946K
0.8% of stake
Aug 8, 2025No plan
John Gordon Freund
Director · sold 11,659 at $34.36
401K
10% of stake
Jun 9, 2025No plan
John Gordon Freund
Director · sold 6,601 at $30.62
202K
5.5% of stake
Mar 20, 2025 – Mar 21, 202510b5-1 plan
Colleen Tupper
EVP & Chief Financial Officer · sold 7,602 at avg $30.03
228K
4.6% of stake
Mar 20, 2025 – Mar 21, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 20,808 at avg $30.03
625K
17% of stake
Mar 14, 202510b5-1 plan
Colleen Tupper
EVP & Chief Financial Officer · sold 977 at $30.00
29K
0.6% of stake
Mar 14, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 2,255 at $30.00
68K
1.8% of stake
Mar 11, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 15,387 at $30.00
462K
11% of stake
Mar 11, 202510b5-1 plan
Colleen Tupper
EVP & Chief Financial Officer · sold 10,445 at $30.01
313K
5.9% of stake
Mar 6, 2025 – Mar 7, 202510b5-1 plan
Colleen Tupper
EVP & Chief Financial Officer · sold 3,453 at avg $30.00
104K
1.9% of stake
Mar 6, 2025 – Mar 7, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 5,643 at avg $30.00
169K
3.8% of stake
Mar 6, 202510b5-1 plan
Scott Dreyer
EVP & Chief Commercial Officer · sold 15,387 at $30.00
462K
11% of stake
Mar 4, 2025 – Mar 6, 2025No plan
Shirley R. Kuhlmann
EVP and General Counsel · sold 86,067 at avg $28.20
$2.43M
44% of stake
Jan 10, 202510b5-1 plan
Shirley R. Kuhlmann
EVP and General Counsel · sold 27,500 at avg $33.04
909K
19% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch COLL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with COLL

CompareIntrinsic value

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

EBSEmergent BioSolutions Inc.

$5.90-5.60%37

KNSAKiniksa Pharmaceuticals International, plc

$96.12+3.03%71

PCRXPacira BioSciences Inc.

$36.40+0.03%58

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

Held by ETFs

COLL is in 76 US ETFs. The largest of them, with COLL's weight in each:

Spot a number that looks wrong? Check it in COLL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing COLL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.